Literature DB >> 22933860

Hepatitis C virus infection and nonalcoholic steatohepatitis.

Anish Patel1, Stephen A Harrison.   

Abstract

Nonalcoholic fatty-liver disease (NAFLD) is one of the most prevalent liver diseases in the Western hemisphere. The rising rates of obesity and diabetes mellitus correlate with the increasing incidence of NAFLD, which is the hepatic manifestation of metabolic syndrome. Hepatitis C virus infection is another common cause of liver disease worldwide. Up to 70% of patients with chronic hepatitis C (CHC) will have concomitant steatosis. The presence of NAFLD has been implicated as a cause of lower viral response rates in CHC patients who are treated with pegylated interferon and ribavirin. This review will focus on the factors that lead to NAFLD in the setting of hepatitis C virus infection, including viral and host factors-in particular, inflammatory mediators, cytokines, and lipid peroxidation. This paper will also discuss the implications of NAFLD and nonalcoholic steatohepatitis regarding fibrosis progression, risk of hepatocellular carcinoma, and limitations with antiviral therapy.

Entities:  

Keywords:  Hepatitis C virus; insulin resistance; nonalcoholic fatty-liver disease; nonalcoholic steatohepatitis

Year:  2012        PMID: 22933860      PMCID: PMC3424424     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  89 in total

1.  Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

Authors:  Stephen A Harrison; Elizabeth M Brunt; Rizwan A Qazi; Dana A Oliver; Brent A Neuschwander-Tetri; Adrian M Di Bisceglie; Bruce R Bacon
Journal:  Clin Gastroenterol Hepatol       Date:  2005-06       Impact factor: 11.382

2.  Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Authors:  Stephen A Harrison; Lorenzo Rossaro; Ke-Qin Hu; Keyur Patel; Hans Tillmann; Sandeep Dhaliwal; Dawn M Torres; Kenneth Koury; Venkata S Goteti; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.

Authors:  L E Adinolfi; R Utili; A Andreana; M F Tripodi; M Marracino; M Gambardella; M Giordano; G Ruggiero
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

4.  Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome.

Authors:  Arun J Sanyal; Melissa J Contos; Richard K Sterling; Velimir A Luketic; Mitchell L Shiffman; R Todd Stravitz; A Scott Mills
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

5.  High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis.

Authors:  V Paradis; G Perlemuter; F Bonvoust; D Dargere; B Parfait; M Vidaud; M Conti; S Huet; N Ba; C Buffet; P Bedossa
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

6.  Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

Authors:  Jason M Hui; Archana Sud; Geoffrey C Farrell; Priyanka Bandara; Karen Byth; James G Kench; Geoffrey W McCaughan; Jacob George
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

7.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.

Authors:  Hashem B El-Serag; Thomas Tran; James E Everhart
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 8.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Stephen A Harrison; Brent A Neuschwander-Tetri
Journal:  Clin Liver Dis       Date:  2004-11       Impact factor: 6.126

9.  The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.

Authors:  Heather M Patton; Keyur Patel; Cynthia Behling; David Bylund; Lawrence M Blatt; Marc Vallée; Shanon Heaton; Andrew Conrad; Paul J Pockros; John G McHutchison
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

10.  Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.

Authors:  Mahmoud Khattab; Mohammed Emad; Asharf Abdelaleem; Mohammed Eslam; Rabab Atef; Yehia Shaker; Lamia Hamdy
Journal:  Liver Int       Date:  2009-11-16       Impact factor: 5.828

View more
  15 in total

1.  The role of disease severity in influencing body mass index in people with haemophilia: a single-institutional cross-sectional study.

Authors:  M McNamara; A Antun; C L Kempton
Journal:  Haemophilia       Date:  2013-10-14       Impact factor: 4.287

2.  Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics.

Authors:  Newaz Hossain; Bharat Puchakayala; Pushpjeet Kanwar; Siddharth Verma; George Abraham; Zhanna Ivanov; Muhammad Obaid Niaz; Smruti R Mohanty
Journal:  Dig Dis Sci       Date:  2017-09-14       Impact factor: 3.199

Review 3.  Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades.

Authors:  Yoshihiro Ikura
Journal:  World J Hepatol       Date:  2014-12-27

4.  Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders.

Authors:  Srinevas K Reddy; Min Zhan; H Richard Alexander; Samer S El-Kamary
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 5.  Infections at the nexus of metabolic-associated fatty liver disease.

Authors:  Robim M Rodrigues; Tamara Vanhaecke; Joost Boeckmans; Matthias Rombaut; Thomas Demuyser; Baptist Declerck; Denis Piérard; Vera Rogiers; Joery De Kock; Luc Waumans; Koen Magerman; Reinoud Cartuyvels; Jean-Luc Rummens
Journal:  Arch Toxicol       Date:  2021-05-24       Impact factor: 5.153

6.  Retrospective study of the associations between hepatitis C virus infection and metabolic factors.

Authors:  Shira Yair-Sabag; Elchanan Nussinson; Ofir Ben-Assuli; Fahmi Shibli; Azmi Shahbari; Shira Zelber-Sagi
Journal:  World J Hepatol       Date:  2016-10-28

7.  Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis.

Authors:  Dana L Sharma; Hari Vishal Lakhani; Rebecca L Klug; Brian Snoad; Rawan El-Hamdani; Joseph I Shapiro; Komal Sodhi
Journal:  J Clin Cell Immunol       Date:  2017-09-29

8.  Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas.

Authors:  Anna Kakehashi; Vasily E Stefanov; Naomi Ishii; Takahiro Okuno; Hideki Fujii; Kazuaki Kawai; Norifumi Kawada; Hideki Wanibuchi
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

9.  Hepatitis C Virus Infection Increases c-Jun N-Terminal Kinase (JNK) Phosphorylation and Accentuates Hepatocyte Lipoapoptosis.

Authors:  Hiroko Takaki; Yuko Akazawa; Youko Kido; Mami Morishita; Takuya Honda; Hidetaka Shibata; Satoshi Miuma; Hisamitsu Miyaaki; Naota Taura; Hisayoshi Kondo; Kazuhiko Nakao
Journal:  Med Sci Monit       Date:  2017-09-21

10.  S100A4 Gene is Crucial for Methionine-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.

Authors:  Yin Hua Zhang; De Qiang Ma; De Ping Ding; Juan Li; Lin Li Chen; Kang Jian Ao; You You Tian
Journal:  Yonsei Med J       Date:  2018-11       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.